|
Provexis PLC on Wednesday reported a widened interim loss after a late production run weakened revenue, but said it plans at least three further production runs in 2026 amid customer demand. The Reading, England-based producer of heart-health functional food ingredient Fruitflow said pretax loss widened to £307,146 for the six months ended September 30, from £146,649 a year ago. This was largely because the revenue fell 54% to £364,369 from £785,348. Provexis attributed the decline in revenue to lower sales in August and September resulting from a late Fruitflow II SD production run, which was completed two months later than previously anticipated. Further weakening the bottom line, selling and distribution costs rose 23% to £40,298 from £32,811, while share based payment charges more than tripled to £154,716 from £49,207. Looking ahead to 2026, the company said it is planning at least three further production runs of Fruitflow II SD, following ‘numerous sales enquiries from existing and new customers’. The first run of the year is expected to be delivered in February. Provexis said the planned launch of Fruitflow products by Chinese dietary supplement business Byhealth Co Ltd is ‘progressing well’. Byhealth is continuing to work on an ‘extensive regulatory submission’ to China’s market regulation authority, the firm said. Regarding its partnership with dsm-firmenich, Provexis said it has ‘progressed well’ with ‘continuing interest from some significant global customers’. ‘The company is pleased to report on another strong period of progress,’ said Chief Executive Ian Ford. Shares in Provexis rose 0.6% to 0.85 pence on Wednesday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
